Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 240-241-0
CAS number: 16088-62-3
Inhalation studies in animals have shown that propylene oxide produces a spectrum of upper respiratory tract changes, from inflammation and degeneration to metaplasia and neoplasia. Repeated oral administration by gavage in rats induced carcinoma in the epithelium of the forestomach.It is evident that carcinogenic responses to propylene oxide are primarily confined to the sites of initial contact. Due to its direct-acting nature and its mutagenic activity, the carcinogenic hazard of propylene oxide expressed in animals is considered relevant to humans. In view of the potential genotoxic contribution to the carcinogenic mechanism of propylene oxide, it is not possible to establish an exposure level at which there would be no increased risk of carcinogenicity. Classification according to Annex I of Directive 67/548/EC is proposed as follows: Carc. Cat. 2; R45 May Cause Cancer.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again